MARKET

CADL

CADL

Candel Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.93
-0.07
-0.70%
After Hours: 10.28 +0.35 +3.52% 17:52 09/24 EDT
OPEN
10.00
PREV CLOSE
10.00
HIGH
10.35
LOW
9.86
VOLUME
100.94K
TURNOVER
--
52 WEEK HIGH
14.78
52 WEEK LOW
5.51
MARKET CAP
284.89M
P/E (TTM)
-13.9154
1D
5D
1M
3M
1Y
5Y
Aethlon Medical, Onconova Therapeutics leads healthcare gainers; ReWalk Robotics, InnovAge among major losers
Gainers: Aethlon Medical (NASDAQ:AEMD) +36%, Onconova Therapeutics (NASDAQ:ONTX) +35%, Dynavax Technologies (NASDAQ:DVAX) +23%, Candel Therapeutics (NASDAQ:CADL) +22%, BioCardia (NASDAQ:BCDA) +11%. Losers: ReWalk Robotics (NASDAQ:RWLK) -27%, InnovAge (NASD...
Seekingalpha · 3d ago
72 Biggest Movers From Yesterday
Gainers
Benzinga · 09/14 08:50
Candel Therapeutics Announces Presentations Of Key Clinical Data At AdMeTech And European Association Of Neuro-Oncology Conferences In September 2021
 Candel Therapeutics, Inc. (NASDAQ:CADL), today announced upcoming presentations of clinical data supporting continued clinical advancement of its prostate cancer and brain cancer programs at the following medical
Benzinga · 09/09 12:26
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)
Benzinga · 09/09 12:17
Candel Therapeutics Announces Presentations of Key Clinical Data at AdMeTech and European Association of Neuro-Oncology Conferences in September 2021
Dr. Scott E. Eggener to present safety data from phase 2 clinical trial of CAN-2409 in patients with localized, low to intermediate risk prostate cancer undergoing active surveillance at AdMeTech Foundation’s Fifth Global Summit on Precision Diagnosis and ...
GlobeNewswire · 09/09 12:00
GSAT, ATER and PXLW among mid-day movers
Gainers: Kadmon (NASDAQ:KDMN) +73%. ICU Medical (NASDAQ:ICUI) +32%. Candel Therapeutics (NASDAQ:CADL) +23%. Globalstar (NYSE:GSAT) +22%. Spectrum Brands (NYSE:SPB) +20%. Vinco Ventures (NASDAQ:BBIG) +19%. WISeKey (NASDAQ:WKEY) +14%. SilverBow (NYSE:SBOW) +...
Seekingalpha · 09/08 17:29
Mid-Day Market Update: Crude Oil Rises 1%; REV Group Shares Plummet
Midway through trading Wednesday, the Dow traded down 0.45% to 34,942.88 while the NASDAQ fell 1.09% to 15,207.45. The S&P also fell, dropping 0.55% to 4,495.35.
Benzinga · 09/08 16:17
Kadmon, ICU Medical leads healthcare gainers; INmune Bio, Inozyme Pharma among major losers
Gainers: Kadmon (NASDAQ:KDMN) +73%, ICU Medical (NASDAQ:ICUI) +32%, Candel Therapeutics (NASDAQ:CADL) +17%, Gain Therapeutics (NASDAQ:GANX) +9%, Concord Medical Services (NYSE:CCM) +9%. Losers: INmune Bio (NASDAQ:INMB) -22%, Inozyme Pharma (NASDAQ:INZY) -1...
Seekingalpha · 09/08 14:58
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CADL. Analyze the recent business situations of Candel Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CADL stock price target is 15.33 with a high estimate of 22.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 28.69M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Director
Paul Manning
President/Chief Executive Officer/Director
Paul Tak
Co-Founder/Chief Scientific Officer/Director
Estuardo Aguilar- Cordova
Chief Financial Officer/Primary Contact
John Canepa
Other
Laura Aguilar
No Data
About CADL
Candel Therapeutics, Inc, formerly Advantagene, Inc, is a clinical stage biopharmaceutical company. The Company is focused on helping patients fight cancer with oncolytic viral immunotherapies. Its engineered viruses are designed to induce immunogenic death through viral-mediated cytotoxicity in cancer cells, therefore releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Its approach combines a knowledge of viral immunotherapy with clinical experience across a range of indications. Its product candidate, CAN-2409 program, is in Phase III clinical trial. Its lead HSV product candidate, CAN-3110, is in Phase I clinical trial. The Company also designs candidates based on its HSV platform for the treatment of solid tumors. The Company’s oncolytic viral immunotherapy platforms is based on genetically modified adenovirus and herpes simplex virus (HSV) constructs. Its preclinical models and clinical trials use its approach.

Webull offers kinds of Candel Therapeutics Inc stock information, including NASDAQ:CADL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CADL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CADL stock methods without spending real money on the virtual paper trading platform.